Titre : Franchises et coassurance

Franchises et coassurance : Questions médicales fréquentes

Termes MeSH sélectionnés :

Ophthalmic Solutions
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Franchises et coassurance : Questions médicales les plus fréquentes", "headline": "Franchises et coassurance : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Franchises et coassurance : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-08", "dateModified": "2025-04-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Franchises et coassurance" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Participation aux coûts", "url": "https://questionsmedicales.fr/mesh/D017047", "about": { "@type": "MedicalCondition", "name": "Participation aux coûts", "code": { "@type": "MedicalCode", "code": "D017047", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.219.521.576.090" } } }, "about": { "@type": "MedicalCondition", "name": "Franchises et coassurance", "alternateName": "Deductibles and Coinsurance", "code": { "@type": "MedicalCode", "code": "D003669", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "J Frank Wharam", "url": "https://questionsmedicales.fr/author/J%20Frank%20Wharam", "affiliation": { "@type": "Organization", "name": "Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA." } }, { "@type": "Person", "name": "Alisa B Busch", "url": "https://questionsmedicales.fr/author/Alisa%20B%20Busch", "affiliation": { "@type": "Organization", "name": "Department of Health Care Policy, Harvard Medical School." } }, { "@type": "Person", "name": "Fang Zhang", "url": "https://questionsmedicales.fr/author/Fang%20Zhang", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Dennis Ross-Degnan", "url": "https://questionsmedicales.fr/author/Dennis%20Ross-Degnan", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Mark K Meiselbach", "url": "https://questionsmedicales.fr/author/Mark%20K%20Meiselbach", "affiliation": { "@type": "Organization", "name": "Health Policy and Management, Johns Hopkins University, Baltimore, Maryland, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Diquafosol ophthalmic solution enhances mucin expression via ERK activation in human conjunctival epithelial cells with hyperosmotic stress.", "datePublished": "2022-06-30", "url": "https://questionsmedicales.fr/article/36034736", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": null } }, { "@type": "ScholarlyArticle", "name": "UV spectrophotometric methods for simultaneous determination of ketorolac tromethamine and olopatadine hydrochloride: Application of multiple standard addition for assay of ophthalmic solution.", "datePublished": "2023-10-24", "url": "https://questionsmedicales.fr/article/37875539", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-45378-8" } }, { "@type": "ScholarlyArticle", "name": "The efficacy of bimatoprost ophthalmic solution combined with NB-UVB phototherapy in non-segmental and segmental vitiligo: a single-blind randomized controlled study.", "datePublished": "2023-04-20", "url": "https://questionsmedicales.fr/article/37081101", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-32591-8" } }, { "@type": "ScholarlyArticle", "name": "Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1).", "datePublished": "2022-08-10", "url": "https://questionsmedicales.fr/article/35965392", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/ICO.0000000000003097" } }, { "@type": "ScholarlyArticle", "name": "Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study.", "datePublished": "2022-06-18", "url": "https://questionsmedicales.fr/article/35716319", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12325-022-02194-2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Organisations et économie des soins de santé", "item": "https://questionsmedicales.fr/mesh/D004472" }, { "@type": "ListItem", "position": 3, "name": "Économie", "item": "https://questionsmedicales.fr/mesh/D004467" }, { "@type": "ListItem", "position": 4, "name": "Financement organisé", "item": "https://questionsmedicales.fr/mesh/D005381" }, { "@type": "ListItem", "position": 5, "name": "Assurance", "item": "https://questionsmedicales.fr/mesh/D007341" }, { "@type": "ListItem", "position": 6, "name": "Participation aux coûts", "item": "https://questionsmedicales.fr/mesh/D017047" }, { "@type": "ListItem", "position": 7, "name": "Franchises et coassurance", "item": "https://questionsmedicales.fr/mesh/D003669" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Franchises et coassurance - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Franchises et coassurance", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-03", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Franchises et coassurance", "description": "Qu'est-ce qu'une franchise en assurance santé ?\nComment fonctionne la coassurance ?\nQuelle est la différence entre franchise et coassurance ?\nComment sont calculées les franchises ?\nLes franchises sont-elles remboursables ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Ophthalmic+Solutions&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Franchises et coassurance", "description": "Quels sont les impacts d'une franchise élevée ?\nComment la coassurance affecte-t-elle les patients ?\nLes patients ressentent-ils du stress à cause des franchises ?\nLes franchises influencent-elles la santé des patients ?\nY a-t-il des symptômes financiers liés à la coassurance ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Ophthalmic+Solutions&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Franchises et coassurance", "description": "Comment éviter des frais élevés de franchise ?\nLes bilans de santé sont-ils couverts sans franchise ?\nComment éduquer les patients sur les franchises ?\nLes programmes de prévention réduisent-ils les coûts ?\nComment les patients peuvent-ils planifier leurs soins ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Ophthalmic+Solutions&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Franchises et coassurance", "description": "Comment choisir un plan avec franchise ?\nLes traitements préventifs sont-ils couverts ?\nComment réduire les coûts de coassurance ?\nLes médicaments sont-ils soumis à la franchise ?\nLes soins d'urgence sont-ils affectés par la coassurance ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Ophthalmic+Solutions&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Franchises et coassurance", "description": "Quelles complications peuvent survenir avec des franchises élevées ?\nLa coassurance peut-elle entraîner des complications financières ?\nLes patients évitent-ils des soins à cause des coûts ?\nComment les complications de santé affectent-elles les coûts ?\nLes complications dues à la coassurance sont-elles fréquentes ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Ophthalmic+Solutions&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Franchises et coassurance", "description": "Quels facteurs augmentent les coûts de franchise ?\nComment le choix de l'assurance affecte-t-il les coûts ?\nLes maladies chroniques augmentent-elles les frais ?\nLes jeunes adultes ont-ils des franchises plus basses ?\nLes habitudes de santé influencent-elles les coûts ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Ophthalmic+Solutions&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Qu'est-ce qu'une franchise en assurance santé ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "C'est le montant que le patient doit payer avant que l'assurance ne couvre les frais." } }, { "@type": "Question", "name": "Comment fonctionne la coassurance ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "C'est le pourcentage des frais médicaux que le patient doit payer après la franchise." } }, { "@type": "Question", "name": "Quelle est la différence entre franchise et coassurance ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "La franchise est un montant fixe, tandis que la coassurance est un pourcentage des frais." } }, { "@type": "Question", "name": "Comment sont calculées les franchises ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont généralement fixées par le contrat d'assurance et varient selon les plans." } }, { "@type": "Question", "name": "Les franchises sont-elles remboursables ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, les montants de franchise ne sont pas remboursés par l'assurance." } }, { "@type": "Question", "name": "Quels sont les impacts d'une franchise élevée ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une franchise élevée peut dissuader les patients de consulter des soins médicaux." } }, { "@type": "Question", "name": "Comment la coassurance affecte-t-elle les patients ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut entraîner des coûts supplémentaires pour les patients lors de soins médicaux." } }, { "@type": "Question", "name": "Les patients ressentent-ils du stress à cause des franchises ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les coûts imprévus peuvent causer de l'anxiété financière chez les patients." } }, { "@type": "Question", "name": "Les franchises influencent-elles la santé des patients ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent limiter l'accès aux soins, affectant ainsi la santé globale des patients." } }, { "@type": "Question", "name": "Y a-t-il des symptômes financiers liés à la coassurance ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des frais médicaux imprévus peuvent entraîner des difficultés financières." } }, { "@type": "Question", "name": "Comment éviter des frais élevés de franchise ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Choisissez un plan avec une franchise adaptée à vos besoins médicaux prévisibles." } }, { "@type": "Question", "name": "Les bilans de santé sont-ils couverts sans franchise ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Souvent, les bilans de santé préventifs sont couverts sans frais de franchise." } }, { "@type": "Question", "name": "Comment éduquer les patients sur les franchises ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Fournissez des informations claires sur les coûts et les options d'assurance disponibles." } }, { "@type": "Question", "name": "Les programmes de prévention réduisent-ils les coûts ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent réduire les coûts à long terme en évitant des soins coûteux." } }, { "@type": "Question", "name": "Comment les patients peuvent-ils planifier leurs soins ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Ils doivent évaluer leurs besoins et choisir des soins en fonction de leur plan d'assurance." } }, { "@type": "Question", "name": "Comment choisir un plan avec franchise ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Évaluez vos besoins médicaux et comparez les coûts des franchises et coassurances." } }, { "@type": "Question", "name": "Les traitements préventifs sont-ils couverts ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Souvent, les traitements préventifs sont couverts sans franchise, selon le plan." } }, { "@type": "Question", "name": "Comment réduire les coûts de coassurance ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Choisissez des soins dans le réseau de votre assurance pour réduire les frais." } }, { "@type": "Question", "name": "Les médicaments sont-ils soumis à la franchise ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent être soumis à la franchise selon le plan d'assurance." } }, { "@type": "Question", "name": "Les soins d'urgence sont-ils affectés par la coassurance ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les soins d'urgence peuvent entraîner des frais de coassurance après la franchise." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des franchises élevées ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les patients peuvent retarder des soins nécessaires, entraînant des complications de santé." } }, { "@type": "Question", "name": "La coassurance peut-elle entraîner des complications financières ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des frais imprévus peuvent causer des dettes médicales importantes." } }, { "@type": "Question", "name": "Les patients évitent-ils des soins à cause des coûts ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les coûts élevés peuvent dissuader les patients de rechercher des soins médicaux." } }, { "@type": "Question", "name": "Comment les complications de santé affectent-elles les coûts ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des complications peuvent entraîner des frais médicaux supplémentaires et imprévus." } }, { "@type": "Question", "name": "Les complications dues à la coassurance sont-elles fréquentes ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, de nombreux patients rencontrent des difficultés à payer leurs frais médicaux." } }, { "@type": "Question", "name": "Quels facteurs augmentent les coûts de franchise ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'âge, les antécédents médicaux et le type de soins peuvent influencer les coûts." } }, { "@type": "Question", "name": "Comment le choix de l'assurance affecte-t-il les coûts ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Différents plans d'assurance ont des franchises et coassurances variées, influençant les coûts." } }, { "@type": "Question", "name": "Les maladies chroniques augmentent-elles les frais ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients avec des maladies chroniques peuvent faire face à des frais plus élevés." } }, { "@type": "Question", "name": "Les jeunes adultes ont-ils des franchises plus basses ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Souvent, les jeunes adultes choisissent des plans avec des franchises plus basses." } }, { "@type": "Question", "name": "Les habitudes de santé influencent-elles les coûts ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des habitudes de santé positives peuvent réduire les frais médicaux à long terme." } } ] } ] }

Sources (10000 au total)

Diquafosol ophthalmic solution enhances mucin expression via ERK activation in human conjunctival epithelial cells with hyperosmotic stress.

To evaluate the effect of diquafosol tetrasodium on the expression of secretory and membrane-associated mucins in multi-layered cultures of primary human conjunctival epithelial cells (HCEC) using int... HCECs were treated with hyperosmotic stress (400 mOsm/l) for 24 h after air-liquid interface cell culture followed by treatment with diquafosol. HCECs were stimulated for 1 h with or without PD98059, ... Hyperosmotic stressed HCECs demonstrated increased MUC5AC secretion and gene expression when treated with diquafosol. MUC1 mRNA levels increased significantly at 24 h (p<0.01), and expression of MUC16... ERK signaling may regulate the expression levels of MUC1, MUC16, and MUC5AC induced by diquafosol in hyperosmotic stressed HCECs....

UV spectrophotometric methods for simultaneous determination of ketorolac tromethamine and olopatadine hydrochloride: Application of multiple standard addition for assay of ophthalmic solution.

Ophthalmic preparations that contain ketorolac tromethamine (KET) and olopatadine HCl (OLO) are used to relieve seasonal allergies and allergic conjunctivitis. Simultaneous quantification of KET and O...

The efficacy of bimatoprost ophthalmic solution combined with NB-UVB phototherapy in non-segmental and segmental vitiligo: a single-blind randomized controlled study.

Bimatoprost ophthalmic solution 0.03% (PGF2α analogues) combined with narrowband ultraviolet B (NB-UVB) was reported to be an effective treatment for vitiligo. To investigate the efficacy and safety o...

Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1).

The purpose of this study was to evaluate the safety and efficacy of lotilaner ophthalmic solution, 0.25%, compared with vehicle for the treatment of Demodex blepharitis.... In this prospective, randomized, controlled, double-masked, phase 2b/3 clinical trial, 421 patients with Demodex blepharitis were randomly assigned in a 1:1 ratio to receive either lotilaner ophthalmi... At day 43, the study group achieved a statistically significantly higher proportion of patients with clinically meaningful collarette cure (81.3% vs. 23.0%; P < 0.0001), complete collarette cure (44.0... Twice-daily treatment with a novel lotilaner ophthalmic solution, 0.25% for 43 days, is safe and effective for the treatment of Demodex blepharitis compared with the vehicle control....

Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study.

DE-089C is a newly developed long-acting formulation of diquafosol ophthalmic solution with less frequent administration (three times daily) than the currently approved and clinically used diquafosol ... This randomized, multicenter, double-masked, placebo-controlled, parallel-group phase 3 study was conducted in Japan. Patients with aqueous-deficient dry eye satisfying Schirmer's test I results ≤ 5 m... The background characteristics of patients in the two groups were similar. Primary endpoint of change in fluorescein corneal staining score at week 4 in the DE-089C group was significantly improved co... The efficacy and safety of DE-089C administered three times daily at half the dosage of DQS in patients with dry eye were confirmed in this study.... Japan Pharmaceutical Information Center ID, JapicCTI-205177....

Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: An interventional study.

To evaluate the concentrations of brimonidine and timolol in the vitreous and aqueous humors after instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution.... This single-arm open-label interventional study included patients with macular holes or idiopathic epiretinal membranes who were scheduled for vitrectomy. Written informed consent was obtained from al... Eight eyes of eight patients (7 phakic eyes and 1 pseudophakic eye) were included in this study. The mean brimonidine concentrations in the vitreous and aqueous humors were 5.04 ± 4.08 nM and 324 ± 17... The majority of patients who received a 0.1% brimonidine tartrate and 0.5% timolol topical fixed-combination ophthalmic solution showed a brimonidine concentration >2 nM in the vitreous humor. Brimoni...

Analysis of risk factors for dry eye disease and effect of diquafosol sodium ophthalmic solution on the tear film after vitrectomy in patients with type 2 diabetes mellitus: a preliminary study.

The purpose of this study was to investigate the risk factors of DM associated dry eye syndrome (DMDES) and to explore the effect of diquafosol sodium ophthalmic solution (DQS) on patients with DMDES ... Totally 107 patients (107 eyes) received vitrectomy. The data of age, gender, left/right eye, duration of DM, duration of vitrectomy, fasting blood glucose and glycosylated hemoglobin were collected a... Gender, duration of DM and glycosylated hemoglobin were relevant factors of DMDES (P < 0.05). At 1, 2 and 3 months postoperatively, NIBUT and TMH of experimental group were significantly higher than c... These results suggest that gender, duration of DM and glycosylated hemoglobin are risk factors for DMDES. Postoperative instillation of DQS can improve the tear film quality in patients with DMDES aft...

0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial.

We determined the efficacy and safety of 0.1% RGN-259 ophthalmic solution (containing the regenerative protein thymosin ß4) in promoting the healing of persistent epithelial defects in patients with S...

Protocol for a parallel assignment prospective, randomised, comparative trial to evaluate the safety and efficacy of intense pulsed light (IPL) combined with 3% diquafosol (DQS) ophthalmic solution in dry eye syndrome.

Evaporative dry eye (EDE) is common and can lead to ocular pain, decreased visual quality and reduced quality of life. Intense pulsed light (IPL) and 3% diquafosol ophthalmic solution have been found ... A randomised clinical trial will be performed at He Eye Specialist Hospital in Shenyang. 360 dry eye disease patients will be equally divided randomly into the IPL group, DQS group (3% diquafosol opht... This study aimed to assess whether the combination of IPL with 3% diquafosol ophthalmic solution (study group), IPL+ (study group), is more effective than IPL (active control group) or DQS (active con... Management of dry eye with IPL combined with 3% diquafosol ophthalmic solution, registered on 23 January 2023. Ethics approval number: IRB (2022) K029.01. The study's findings will be shared regardles... NCT05694026....